Publisher
Springer Science and Business Media LLC
Reference79 articles.
1. Lord, R. V., Brabender, J., Gandara, D., et al. (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clinical Cancer Research, 8, 2286–2291.
2. Rosell, R., Taron, M., Barnadas, A., et al. (2003). Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer. Cancer Control, 10, 297–305.
3. Michor, F., Nowak, M. A., & Iwasa, Y. (2006). Evolution of resistance to cancer therapy. Current Pharmaceutical Design, 12, 261–271.
4. Olaussen, K. A., Dunant, A., Fouret, P., et al. (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. New England Journal of Medicine, 355, 983–991.
5. Handra-Luca, A., Hernandez, J., Mountzios, G., et al. (2007). Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clinical Cancer Research, 13, 3855–3859.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献